Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis

References

• DaviesJMGoldbergRMTreatment of metastatic colorectal cancerSemin Oncol201138455256021810514
   PubMed Web of Science ®Google Scholar
• SavilleMLietzauJPludaJTreatment of HIV-associated Kaposi’s sarcoma with paclitaxelLancet1995346896626287603142
   PubMed Web of Science ®Google Scholar
• AhmedAAWangXLuZModulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxelCancer Res201171175806581721775522
   PubMed Web of Science ®Google Scholar
• MielgoATorresVAClairKBarberoSStupackDGPaclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubulesOncogene200928403551356219668227
   PubMed Web of Science ®Google Scholar
• MoktanSRyppaCKratzFRaucherDA thermally responsive biopolymer conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests cell cycle, and induces apoptosisInvest New Drugs201230123624820938714
   PubMed Web of Science ®Google Scholar
• GuptaNHatoumHDyGKFirst line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxelInt J Nanomedicine2014920922124399877
   PubMed Web of Science ®Google Scholar
• ZhangCAwasthiNSchwarzMASchwarzREThe dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancerInt J Oncol20134351627163524042258
   PubMed Web of Science ®Google Scholar
• PalumboRSottotettiFTrifiroGNanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of lifeDrug Des Devel Ther2015921892199
   PubMed Web of Science ®Google Scholar
• PeltierSOgerJ-MLagarceFCouetWBenoîtJ-PEnhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsulesPharm Res20062361243125016715372
   PubMed Web of Science ®Google Scholar
• BuHHeXZhangZYinQYuHLiYA TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancerInt J Pharm20144711–220621324866272
   PubMedGoogle Scholar
• GantaSAmijiMCoadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cellsMol Pharm20096392893919278222
   PubMed Web of Science ®Google Scholar
• ChoudhuryHGorainBKarmakarSImprovement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platformInt J Pharm20144601–213114324239580
   PubMedGoogle Scholar
• DiasMLCarvalhoJPRodriguesDGGrazianiSRMaranhaoRCPharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancersCancer Chemother Pharmacol200759110511116699792
   PubMed Web of Science ®Google Scholar
• DesaiAVyasTAmijiMCytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulationsJ Pharm Sci20089772745275617854074
   PubMed Web of Science ®Google Scholar
• DeepaGAshwanikumarNPillaiJJKumarGSPolymer nanoparticles – a novel strategy for administration of paclitaxel in cancer chemotherapyCurr Med Chem201219366207621322834822
   PubMed Web of Science ®Google Scholar
• GuoXYWangPDuQGPaclitaxel and gemcitabine combinational drug-loaded mucoadhesive delivery system in the treatment of colon cancersDrug Res2015654199204
   Google Scholar
• GoncalvesABraguerDCarlesGAndreNPrevotCBriandCCaspase-8 activation independent of CD95/CD95-L interaction during paclitaxel-induced apoptosis in human colon cancer cells (HT29-D4)Biochem Pharmacol200060111579158411077039
   PubMed Web of Science ®Google Scholar
• FengSSMuLWinKYHuangGNanoparticles of biodegradable polymers for clinical administration of paclitaxelCurr Med Chem200411441342414965222
   PubMed Web of Science ®Google Scholar
• XuRSatoNYanaiKEnhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cellsAnticancer Res200929126127019331159
   PubMed Web of Science ®Google Scholar
• ChenJPotential value and limitation of dual inhibitors of PI3K and mTOR in the treatment of cancerCurr Cancer Drug Targets201313211712023215718
   PubMed Web of Science ®Google Scholar
• BuZJiJTherapeutic implications of mTOR inhibitors in the treatment of gastric cancerCurr Cancer Drug Targets201313212112523215721
   PubMed Web of Science ®Google Scholar
• ChoDCMierJWDual inhibition of PI3-kinase and mTOR in renal cell carcinomaCurr Cancer Drug Targets201313212614223259857
   PubMed Web of Science ®Google Scholar
• ElfikyAAJiangZThe PI3 kinase signaling pathway in prostate cancerCurr Cancer Drug Targets201313215716423215719
   PubMed Web of Science ®Google Scholar
• PageCLinHJJinYOverexpression of Akt/AKT can modulate chemotherapy-induced apoptosisAnticancer Res200020140741610769688
   PubMedGoogle Scholar
• BrognardJClarkASNiYDennisPAAkt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiationCancer Res200161103986399711358816
   PubMed Web of Science ®Google Scholar
• ChapuisNTamburiniJGreenASDual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemiaClin Cancer Res201016225424543520884625
   PubMed Web of Science ®Google Scholar
• ManaraMCNicolettiGZambelliDNVP-BEZ235 as a new therapeutic option for sarcomasClin Cancer Res201016253054020068094
   PubMed Web of Science ®Google Scholar
• WuPHuY-ZPI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progressCurr Med Chem201017354326434120939811
   PubMed Web of Science ®Google Scholar
• RoperJRichardsonMPWangWVThe dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancerPLoS One201169e2513221966435
   PubMed Web of Science ®Google Scholar
• ChenJShaoRLiLXuZPGuWEffective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathwaysInt J Nanomedicine201493403341125075187
   PubMed Web of Science ®Google Scholar
• KudohAOishiTItamochiHDual inhibition of phosphatidylinositol 3′-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovaryInt J Gynecol Cancer201424344445324552895
   PubMed Web of Science ®Google Scholar
• SkouraESyrigosKNSaifMWPreclinical research in treatment of pancreatic cancerJOP201314438438723846933
   PubMedGoogle Scholar
• LinSFHuangYYLinJDChouTCHsuehCWongRJUtility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapyPLoS One2012710e4672623077520
   PubMed Web of Science ®Google Scholar
• MairaS-MStaufferFBrueggenJIdentification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activityMol Cancer Ther2008771851186318606717
   PubMed Web of Science ®Google Scholar
• WangTHChanYHChenCWPaclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathwaysOncogene200625354857486616547493
   PubMed Web of Science ®Google Scholar
• OzcelikBTurkyilmazCOzgunMTPrevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonistFertil Steril20109351609161419339002
   PubMed Web of Science ®Google Scholar
• ChoiSJChoyJHLayered double hydroxide nanoparticles as target-specific delivery carriers: uptake mechanism and toxicityNanomedicine (Lond)20116580381421793673
   PubMed Web of Science ®Google Scholar
• GantaSDevalapallyHAmijiMCurcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulationJ Pharm Sci201099114630464120845461
   PubMed Web of Science ®Google Scholar
• ChenJHXQiaoLKatsifisAInsulin caused drug resistance to oxaliplatin in colon cancer cell HT29J Gastrointest Oncol20112273322811824
   PubMedGoogle Scholar
• ChenJKatsifisAHuCHuangXFInsulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathwayCurr Drug Discov Technol20118211912521513489
   PubMedGoogle Scholar
• BartucciMSvenssonSRicci-VitianiLObesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cellsEndocr Relat Cancer201017382383320603394
   PubMed Web of Science ®Google Scholar
• MuellerABachmannELinnigMSelective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell linesCancer Chemother Pharmacol20126961601161522543857
   PubMed Web of Science ®Google Scholar
• RajeshDSchellKVermaARas mutation, irrespective of cell type and p53 status, determines a cell’s destiny to undergo apoptosis by okadaic acid, an inhibitor of protein phosphatase 1 and 2AMol Pharmacol199956351552510462539
   PubMed Web of Science ®Google Scholar
• BhattacharyaBAkramMBalasubramanianIPharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cellsCancer Biol Ther2012131344222336586
   PubMed Web of Science ®Google Scholar
• ZouZ-QZhangX-HWangFA novel dual PI3Kα/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cellsInt J Mol Med20092419710119513541
   PubMed Web of Science ®Google Scholar
• ParkSChapuisNBardetVPI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AMLLeukemia20082291698170618548104
   PubMed Web of Science ®Google Scholar
• SchwabJAntonescuCBolandPCombination of PI3K/mTOR inhibition demonstrates efficacy in human chordomaAnticancer Res20092961867187119528441
   PubMed Web of Science ®Google Scholar
• SantiskulvongCKonecnyGEFeketeMDual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinomaClin Cancer Res20111782373238421372221
   PubMed Web of Science ®Google Scholar
• WanderSAHennessyBTSlingerlandJMNext-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategyJ Clin Invest201112141231214121490404
   PubMed Web of Science ®Google Scholar
• SerraVScaltritiMPrudkinLPI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerOncogene201130222547255721278786
   PubMed Web of Science ®Google Scholar